Engineered aptimer targets malignant and tumor-associated T cells
6/05/2014
The transcription factor STAT3 mediates tumor survival, proliferation, invasion, and immunosuppression, and is persistently activated in tumor cells and tumor-associated immune cells.
New path discovered to stop breast cancer cells from invading organs
6/05/2014
The primary cause of death from breast cancer is the spread of tumor cells from the breast to other organs in the body.
What is science doing to improve the health and lives of cancer survivors?
6/04/2014
Following this week's National Cancer Survivors Day, we examine the latest research aimed at tackling health issues commonly experienced by cancer survivors.
New insight into drug resistance in metastatic melanoma
6/04/2014
A study by scientists in Manchester has shown how melanoma drugs can cause the cancer to progress once a patient has stopped responding to treatment.
Researchers deliver double dose of lung cancer discoveries
6/04/2014
Researchers at UCLA's Jonsson Comprehensive Cancer Center (JCCC) are reporting exciting dual discoveries in the treatment of non-small-cell lung cancer (NSCLC), which accounts for about 85 percent...
CALGB 80405, a large, independent, phase III study, designed to assess the superiority in overall survival (OS) of cetuximab over Avastin® (bevacizumab) when combined with either FOLFOX or...
Researchers use new simple cost effective technology to unravel cancer through standard imaging
6/04/2014
Researchers at Maastricht University Medical Center+ (Maastricht UMC+) and the MAASTRO Clinic have developed a new medical imaging analysis method to predict the risk of dying of cancer in patients.
A rarely-studied aspect of brain tumour research, until now, concerns the quality of life and mental state of patients and family members providing care.
A new investigational immunotherapy MPDL3280A has been shown to shrink tumours in 43% of people (13/30) who had previously been treated for advanced urothelial bladder cancer (UBC) with a specific...
Nonadherence to leukemia maintenance medication in childhood triples relapse risk
6/04/2014
An estimated 25 percent of children in remission from acute lymphocytic leukemia (ALL) are missing too many doses of an essential maintenance medication that minimizes their risk of relapse...